The radiologically isolated syndrome: revised diagnostic criteria.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 08 2023
Historique:
received: 06 11 2022
revised: 26 01 2023
accepted: 05 02 2023
medline: 3 8 2023
pubmed: 4 3 2023
entrez: 3 3 2023
Statut: ppublish

Résumé

The radiologically isolated syndrome (RIS) was defined in 2009 as the presence of asymptomatic, incidentally identified demyelinating-appearing white matter lesions in the CNS within individuals lacking symptoms typical of multiple sclerosis (MS). The RIS criteria have been validated and predict the transition to symptomatic MS reliably. The performance of RIS criteria that require fewer MRI lesions is unknown. 2009-RIS subjects, by definition, fulfil three to four of four criteria for 2005 dissemination in space (DIS) and subjects fulfilling only one or two lesions in at least one 2017 DIS location were identified within 37 prospective databases. Univariate and multivariate Cox regression models were used to identify predictors of a first clinical event. Performances of different groups were calculated. Seven hundred and forty-seven subjects (72.2% female, mean age 37.7 ± 12.3 years at the index MRI) were included. The mean clinical follow-up time was 46.8 ± 45.4 months. All subjects had focal T2 hyperintensities suggestive of inflammatory demyelination on MRI; 251 (33.6%) fulfilled one or two 2017 DIS criteria (designated as Groups 1 and 2, respectively), and 496 (66.4%) fulfilled three or four 2005 DIS criteria representing 2009-RIS subjects. Group 1 and 2 subjects were younger than the 2009-RIS group and were more likely to develop new T2 lesions over time (P < 0.001). Groups 1 and 2 were similar regarding survival distribution and risk factors for transition to MS. At 5 years, the cumulative probability for a clinical event was 29.0% for Groups 1 and 2 compared to 38.7% for 2009-RIS (P = 0.0241). The presence of spinal cord lesions on the index scan and CSF-restricted oligoclonal bands in Groups 1-2 increased the risk of symptomatic MS evolution at 5 years to 38%, comparable to the risk of development in the 2009-RIS group. The presence of new T2 or gadolinium-enhancing lesions on follow-up scans independently increased the risk of presenting with a clinical event (P < 0.001). The 2009-RIS subjects or Groups 1 and 2 with at least two of the risk factors for a clinical event demonstrated better sensitivity (86.0%), negative predictive value (73.1%), accuracy (59.8%) and area under the curve (60.7%) compared to other criteria studied. This large prospective cohort brings Class I evidence that subjects with fewer lesions than required in the 2009 RIS criteria evolve directly to a first clinical event at a similar rate when additional risk factors are present. Our results provide a rationale for revisions to existing RIS diagnostic criteria.

Identifiants

pubmed: 36864688
pii: 7067893
doi: 10.1093/brain/awad073
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3431-3443

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Christine Lebrun-Frénay (C)

Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.

Darin T Okuda (DT)

Neuroinnovation Program, Multiple Sclerosis, and Neuroimmunology Imaging Program, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Aksel Siva (A)

Department of Neurology, Istanbul University Cerrahpasa School of Medicine, 34098 Istanbul, Turkey.

Cassandre Landes-Chateau (C)

Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.

Christina J Azevedo (CJ)

Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Lydiane Mondot (L)

Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.

Clarisse Carra-Dallière (C)

Neurology MS Clinic, Montpellier University Hospital, 34295 Montpellier, France.
University of Montpellier (MUSE), 34295 Montpellier, France.

Helene Zephir (H)

Inserm UMR-S 1172 LilNcog, Lille University, Lille University Hospital Precise, 59000 Lille, France.

Celine Louapre (C)

Department of Neurology, Sorbonne University, AP-HP, Pitié-Salpêtrière Hospital, 75013 Paris, France.

Françoise Durand-Dubief (F)

Neurology MS Clinic, Neurological Hospital Pierre Wertheimer, Lyon University Hospital, 69500 Lyon/Bron, France.

Emmanuelle Le Page (E)

Neurology MS Clinic Rennes, Clinical Investigation Centre CIC-P 1414, Rennes University Hospital, 35000 Rennes, France.

Caroline Bensa (C)

Neurology, Rothschild Foundation, 75019 Paris, France.

Aurélie Ruet (A)

Neurology MS Clinic Bordeaux, University Hospital, 33000 Bordeaux, France.
Neurocentre Magendie, Bordeaux University, INSERM, U1215, 33000 Bordeaux, France.

Jonathan Ciron (J)

Neurology MS Clinic, Toulouse University Hospital, 31300 Toulouse, France.
Infinity, INSERM UMR1291, CNRS UMR5051, Toulouse III University, 31300 Toulouse, France.

David A Laplaud (DA)

Neurology, Nantes University Hospital, CIC1314 INSERM, 44000 Nantes, France.
CR2TI INSERM U1064, Nantes University, 44000 Nantes, France.

Olivier Casez (O)

Neurology MS Clinic Grenoble, Grenoble Alpes University Hospital, 38700 Grenoble, France.
T-RAIG, TIMC-IMAG, Grenoble Alpes University, 38700 Grenoble, France.

Guillaume Mathey (G)

Neurology, Nancy University Hospital, 54000 Nancy, France.
Vandoeuvre-Lès-Nancy, Lorraine University, EA 4360 APEMAC, 54000 Nancy, France.

Jerome de Seze (J)

Clinical Investigation Center, Neurology, Strasbourg University Hospital, INSERM 1434, 67200 Strasbourg, France.

Burcu Zeydan (B)

Neurology and Radiology, Mayo Clinic, Rochester, MN 55905, USA.

Naila Makhani (N)

Pediatrics and Neurology, Yale School of Medicine, New Haven, CT 06510, USA.

Melih Tutuncu (M)

Department of Neurology, Istanbul University Cerrahpasa School of Medicine, 34098 Istanbul, Turkey.

Michael Levraut (M)

Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.

Mikael Cohen (M)

Neurology MS Clinic Nice, Pasteur 2 University Hospital, UR2CA-URRIS, Côte d'Azur University, Nice 06002, France.

Eric Thouvenot (E)

Neurology, Nîmes University Hospital, 30900 Nîmes, France.
IGF, Montpellier University, CNRS, INSERM, 34295 Montpellier, France.

Daniel Pelletier (D)

Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

Orhun H Kantarci (OH)

Neurology, Mayo Clinic, Rochester, MN 55905, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH